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ABSTRACT
In the translational process of developing innovative therapies for
DMD (Duchenne muscular dystrophy), the last preclinical validation
step is often carried out in the most relevant animal model of this
human disease, namely the GRMD (Golden Retriever muscular
dystrophy) dog. The disease in GRMD dogs mimics human DMD in
many aspects, including the inter-individual heterogeneity. This last
point can be seen as a drawback for an animal model but is
inherently related to the disease in GRMD dogs closely resembling
that of individuals with DMD. In order to improve the management
of this inter-individual heterogeneity, we have screened a
combination of biomarkers in sixty-one 2-month-old GRMD dogs at
the onset of the disease and a posteriori we addressed their
predictive value on the severity of the disease. Three non-invasive
biomarkers obtained at early stages of the disease were found to be
highly predictive for the loss of ambulation before 6 months of age.
An elevation in the number of circulating CD4+CD49dhi T cells and
a decreased stride frequency resulting in a reduced spontaneous
speed were found to be strongly associated with the severe clinical
form of the disease. These factors can be used as predictive tests
to screen dogs to separate them into groups with slow or fast
disease progression before their inclusion into a therapeutic
preclinical trial, and therefore improve the reliability and translational
value of the trials carried out on this invaluable large animal model.
These same biomarkers have also been described to be predictive
for the time to loss of ambulation in boys with DMD, strengthening
the relevance of GRMD dogs as preclinical models of this
devastating muscle disease.
KEY WORDS: GRMD, DMD, Dystrophin, Dog, Predictive biomarker,
Lymphocyte, CD49d, Gait analysis, Accelerometry
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INTRODUCTION
Duchenne muscular dystrophy (DMD) is the most common genetic
muscular dystrophy, affecting 1 in 3500-5000 male births. It is
caused by mutations in the dystrophin gene, leading to functional
loss or absence of the protein at the sarcolemma of muscle fibers
(Deconinck and Dan, 2007). Individuals with DMD exhibit
progressive muscle weakness leading to the permanent use of a
wheelchair in young adolescents, and to respiratory and heart failure
in young adults. The disease course, although following these
constant patterns, is highly variable between affected individuals, a
striking example being the age for the loss of ambulation, which can
range from 6 to 15 years (Flanigan et al., 2013; Ricotti et al., 2013).
Several recent studies have focused on the phenotypic variability,
and have tried to define stratification criteria (Desguerre et al.,
2009a; Humbertclaude et al., 2012) and identify modulators of
disease severity (Flanigan et al., 2013; Pegoraro et al., 2011) in order
to ultimately increase the success of clinical trials aiming to provide
a therapeutic solution to treat or alleviate DMD.
In order to develop new strategies of treatment, different animal
models have been used. In this context, the dystrophin-deficient dog,
notably the Golden Retriever muscular dystrophy (GRMD) dog,
represents a “translational bridge between mice and humans” (Duan,
2011), because it mimics more closely the human disease than other
existing mammalian models of dystrophin deficiency (Valentine et al.,
1988). GRMD dogs harbor a mutation in the dystrophin gene, and
display dystrophic muscle lesions, inflammatory foci, progressive
fibrosis and fatty infiltration, early locomotor impairment and
premature death due to respiratory or cardiac failure. A wide inter-
individual variability also figures among the numerous similarities
shared by canine and human diseases. At first glance, this inter-
individual variability can be seen as a major obstacle in the evaluation
of therapies at the preclinical stage (Banks and Chamberlain, 2008;
Willmann et al., 2009), but this model could also be relevant in
discovering modulatory factors and modifier genes for this disease.
Taking advantage of this inter-individual heterogeneity to identify
predictive markers of the clinical evolution could help to increase the
robustness of preclinical trials on the one hand, and unveil mechanisms
underlying variations in disease expression on the other hand.
Using this approach, in a cohort of 74 individuals with DMD, we
have shown that the relative number of circulating T cells with a
higher membrane expression level of CD49d (T+/CD49dhi) – the α4
chain of the integrin VLA-4 – correlate with the progression and
prognosis of the disease (F.P.-M., W.S., S.D.S.-B., V.M., T.V., G.B.-
B. et al., unpublished data). This subset of T cells has been shown
to be more prominent in individuals with DMD and, more
importantly, these T-cell subpopulations have an enhanced migration
potential (Pinto-Mariz et al., 2010) and participate to the damaging
inflammatory infiltrate in DMD muscles (F.P.-M., W.S., S.D.S.-B.,
V.M., T.V., G.B.-B. et al., unpublished data). Consequently, CD49d
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can be used in individuals with DMD not only as a muscle
inflammation biomarker, reflecting the progression of the disease,
but can also serve as a predictive biomarker (F.P.-M., W.S., S.D.S.-
B., V.M., T.V., G.B.-B. et al., unpublished data). Another study has
shown that timed motor performances (time to walk 30 feet) in
individuals with DMD were also accurate to predict the time before
loss of ambulation (McDonald et al., 1995).
In GRMD dogs, no such predictive marker has been identified. In
this study, we have assessed the predictive value of the blood
lymphocyte subpopulations expressing high levels of CD49d, and of
gait abnormalities at the onset of the disease. We were successful in
identifying the first predictive biomarkers in GRMD and we provide
a set of three ready-to-use tests that should significantly improve the
quality of the therapeutic trials carried out in GRMD dogs.
RESULTS
Loss of ambulation affects one-third of GRMD dogs, and
occurs before 6 months of age
Inter-individual heterogeneity has been widely described in GRMD
dogs but few clinical stratifications have been proposed (Ambrósio
et al., 2009). In our hands the loss or maintenance of ambulation is
the only clear dichotomic parameter that can define subgroups. This
loss of ambulation occurs in one out of three GRMD dogs, in 85%
of cases before the age of 6 months (Fig. 1). These animals develop
severe contractures and an accelerated progression of their gait
impairment (Barthélémy et al., 2011), leading to the loss of
ambulation and permanent recumbence by 6 months of age. We
defined these particularly devastating clinical presentations (i.e. loss
of ambulation before the age of 6 months) as the ‘severe form’. In
contrast, the remaining GRMD dogs were usually able to maintain
ambulation until their death and were classified as having a
‘moderate form’ of the disease (i.e. dogs with either a loss of
ambulation after the age of 6 months or no loss of ambulation).
The aim of the present study is to assess whether blood and gait
parameters could predict the evolution towards one of these two
clinical forms, at an early stage of the disease. The age of 2 months
was targeted because this is the age of weaning for the puppies and
is also considered as the clinical onset of the disease. From a
practical point of view, it corresponds to the earliest time point for
the longitudinal studies performed in GRMD dogs (Barthélémy et
al., 2011; Thibaud et al., 2012) and a time after which most of the
preclinical trials are designed to begin.
A total of sixty-one 2-month-old GRMD dogs were enrolled in the
study, 15 of which evolved towards the severe form. Thirty-five dogs
were enrolled in the blood study (severe forms n=9/35) and 57 dogs
in the motor study (severe forms n=15/57). The proportion of the
severe form in each group was consistent with the usual observations
that have been made in this colony. Two dogs lost ambulation after 6
months of age (at, respectively, 7.33 and 7.37 months of age), and
were thus categorized as moderate forms. Their late loss of
ambulation was taken into account in the survival analysis.
The proportion of CD4+ T cells with a CD49dhi surface
antigen profile is increased in 2-month-old GRMD dogs with
a severe clinical form
In a first set of experiments, we evaluated the membrane expression
of CD49d (the α4 chain of the VLA-4), comparing the two different
groups of GRMD dogs with healthy controls at 2 months of age. We
found a significantly higher relative number of CD4 T cells
expressing high levels of CD49d (CD4+CD49dhi T cells) in the
blood of dogs with the severe form (SF) of the disease.
Otherwise, no significant differences were observed in the relative
numbers of CD4+CD49dhi T cells between the dogs with the
moderate form (MF) and healthy controls, nor between the relative
numbers of CD8+CD49dhi T cells in the blood of GRMD and
control dogs. In conclusion, a high proportion of circulating
CD4+CD49dhi T cells is an early biomarker of the severe form of
GRMD. The detailed results are given in Table 1, and a graphical
representation is provided in Fig. 2.
Early gait abnormalities are more pronounced in GRMD
dogs with a severe clinical form
During the gait test at 2 months of age, 23 dogs spontaneously
selected to run at a trot, and 33 dogs to run at a bound gallop, while
one dog walked. Seventy percent of dogs (n=30/43) that went on to
develop the moderate form ran at a bound gallop, whereas only 20%
of dogs (n=3/15) that went on to develop the severe form used this
gait type. Therefore, the spontaneous use of the bound gallop at the
age of 2 months can be considered as a good prognosis factor
(χ2=12.48, P=0.0019).
Consistent with these gait differences, the dogs that would
develop the severe form also ran significantly slower than dogs who
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TRANSLATIONAL IMPACT
Clinical issue
Duchenne muscular dystrophy (DMD) is a recessive X-linked genetic
disease that involves the whole striated and cardiac musculature of the
body and that leads to loss of ambulation in young teenagers and death
by the third decade of life. No curative solution is currently available for
this disease. Canine models of DMD, including GRMD (Golden Retriever
muscular dystrophy), closely mimic the human condition and are
particularly relevant to address preclinical questions. Among the
similarities between canine and human diseases, the inter-individual
clinical heterogeneity is a prominent feature; however, this makes results
from preclinical and clinical studies difficult to decipher. In this study, motor
and lymphocytic biomarkers have been evaluated at an early stage of the
canine disease. In addition, their ability to correlate with the severity and
progression of the disease has been assessed to develop a predictive
test that could improve the translational value of preclinical studies.
Results
A population of 61 GRMD dogs was evaluated at 2 months of age
(clinical onset) and was subsequently divided into two subgroups
according to the occurrence of ambulation loss before 6 months of age
(severe form, which affected one fourth of the dogs in the study). An
elevated proportion of circulating lymphocytes expressing high levels of
the integrin CD49d was found predictive of the severe form. In the same
way, low spontaneous gait speed and stride frequency were strongly
associated with the loss of ambulation. Interestingly, these markers have
also been shown to be predictive of the time to loss of ambulation in
individuals with DMD. The reliability of a predictive test based on these
non-invasive and simply obtained markers was assessed, demonstrating
that they can be used to classify dogs based on their future clinical
evolution, with good specificity and sensitivity values. 
Implications and future directions
This study provides ready-to-use tests that can significantly advance the
predictive value of preclinical screenings for DMD candidate therapies.
Indeed, the use of the investigated biomarkers can be realistically
envisioned, either as inclusion criteria, or as covariates in the analysis of
preclinical results. Beyond the possibility to significantly improve the
preclinical phase of clinical studies, the fact that these predictive
biomarkers are shared between dogs and humans reinforces the
translational relevance of this canine model of DMD. Indeed, clinical
heterogeneity could be managed in the same way during preclinical and
clinical steps, optimizing the translation of results. Future experiments
should focus on the mechanisms underlying the clinically relevant
variation of these biomarkers, and could lead to the identification of
















would develop the moderate form (P<0.0001), mainly due to a
significantly lower stride frequency (P<0.0001) associated with a
shorter stride length (P=0.004). Accordingly, the total power was
lower in dogs with the severe form (P=0.0001), as well as the force
index (P=0.017). From a more global point of view, despite the
absence of differences between dogs that would develop the
moderate or severe form regarding regularity and three-axial power
distribution, the gait quality index revealed that the gait was
significantly more impaired in dogs with the severe form (P=0.002),
in accordance with the motor score, which was significantly higher
in these individuals (P=0.003). The serum creatine kinase (CK)
values were slightly decreased (P=0.016) in the GRMD dogs that
would develop the severe form of the disease, and which were
already less mobile.
Detailed results are given in Table 1, and graphical representations
are provided in Fig. 3.
Increased proportion of CD4+CD49dhi T cells, decreased speed
and lower stride frequency at 2 months of age are associated
with an increased risk of early loss of ambulation
After adjustment for body mass index (BMI), number of blood
leucocytes and presence of carpal transient contractures [a common
clinical observation in young GRMD dogs that can impede
locomotion (S.B. and I.B., unpublished data)], the proportion of
CD4+CD49dhi T cells at 2 months of age was linearly and
significantly associated with time to loss of ambulation [adjusted
hazard ratio (aHR) of 1.28 for a 1% increase; 95% confidence
interval (CI), 1.05-1.57; P=0.02].
After the same adjustment, stride frequency at 2 months of age
was linearly and significantly associated with time to loss of
ambulation (aHR of 4.76 for a 1 second−1 decrease; 95% CI, 1.45-
14.29; P<0.01).
Again after the same adjustment, speed normalized by height at
withers (speed/HW) was not linearly but significantly associated with
time to loss of ambulation: dogs with a speed/HW value of 2.5 second−1
and dogs with a speed/HW value of 3 second−1 had an increased risk of
loss of ambulation of 17.70 (95% CI, 3.57-87.80; P<0.01) and 5.28
(95% CI, 2.14-13.05; P<0.01), respectively, compared with dogs with
a speed/HW value of 4 second−1 (Table 2; Fig. 4).
Predictive tests at 2 months of age can be proposed using
the proportion of CD4+CD49dhi, the spontaneous walking
speed and the stride frequency
In order to determine to what extent the lymphocyte and gait
biomarkers could be used as predictive biomarkers for disease
severity, and to assess the value of such a prognostic test, ROC
(receiver operating characteristics) curve analyses were performed.
Ten markers were tested: the proportion of circulating
CD4+CD49dhi and of CD8+CD49dhi lymphocytes, the spontaneous
speed and stride length normalized by the height, the stride
frequency, the motor score, the gait quality index, the total power of
gait, the force index and the serum CK activity. All the ROC
analyses led to statistically significant results, except for the
proportion of CD8+CD49dhi. The areas under the significant ROC
curves ranged from 0.683 (serum CK) to 0.881 (speed/HW). The
graphical representation of the ROC curves is shown in Fig. 5, and
the results of the ROC curve analyses are given in Table 1.
According to the results of the ROC curve analyses, the use of
these three combined markers can be proposed to predict the
severe forms of GRMD as early as 8 weeks of age, each with
interesting characteristics that can answer different needs of a
study design. The speed/HW offers the best combination between
sensitivity and specificity: by positioning a cutoff at 3.2759
seconds−1, the severe form (below this cutoff) can be predicted
with a 86.7% sensitivity and a 87.8% specificity. The specificity
of the test can be increased to lessen the risk of the prediction of
false severe forms by choosing the use of the stride frequency:
with a cutoff frequency of 2.44 cycles/s stride, the severe form can
be predicted with a 90.2% specificity but only a 73.3% sensitivity.
Finally the %CD4+CD49dhi marker can be used with a 12% cutoff
1255
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2 month-old 6 month-old 12 month-old
Early
death
Fig. 1. Loss of ambulation in GRMD dogs and classification in two clinical forms as a function of the occurrence of this clinical event. In the left
panel, the curve represents a Kaplan-Meier curve that shows the percentage of ambulant dogs according to age (n=94 GRMD dogs; S.B. and I.B., 
unpublished data). Loss-of-ambulation events are represented in red, and censored data (either age of still alive and ambulant dogs at the end of the analysis
period, or age at death of ambulant dogs) in green. The loss of ambulation occurs in about one third of the dogs, mainly before 6 months of age (85% of the
dogs with a loss of ambulation). A classification into two sub-phenotypes is proposed and illustrated on the right panel: severe form (red frame) are opposed to


















leading to a 88.9% sensitivity and 68.0% specificity. However this
marker is of particular interest if a 100% specificity is required:
since a 14.97% cutoff can be selected in this case, allowing a
reliable selection of dogs with a predicted loss of ambulation,
despite a large, but in some cases acceptable, proportion of
undetected severe forms (44% sensitivity).
One of these three tests can be chosen, as a function of the
requirements of the study design, so that it is possible to select either
severe or moderate clinical phenotypes, to work on during
preclinical trials. This should improve the analysis of the clinical
outcome of treated dogs, by reducing inter-individual heterogeneity
and increasing the significance of results.
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Table 1. Mean values of the markers at 2 months of age, and statistical results
Stride Total Force 
CD8+CD49dhi CD4+CD49dhi Speed/HW frequency Stride power index Motor Serum CK
(% total CD8+) (% total CD4+) (s−1) (cycles/s) length/HW (W/kg) (N/kg) GQI score (%) (IU/L)
Mean (s.d.) healthy 66.29 (13.31) 10.26 (2.70) 5.68 (0.90) 2.89 (0.20) 1.97 (0.26) 81.5 (18.6) 53.2 (6.3) 1.14 – –
dogs (0.60)
Mean (s.d.) GRMDSF 64.34 (13.11) 15.78 (4.65) 2.81 (0.86) 2.41 (0.44) 1.21 (0.27) 30.9 (13.9) 38.2 (15.4) 3.46 25.9 23,092
(0.99) (6.1) (11,623)
Mean (s.d.) GRMDMF 65.81 (14.35) 10.44 (2.71) 4.50 (1.14) 3.15 (0.52) 1.41 (0.20) 62.1 (25.9) 50.5 (16.2) 2.65 19.8 37,757 
(0.69) (6.1) (31,117)
P-value (GRMDSF vs 0.8094 0.0087 <0.0001 <0.0001 0.0040 0.0001 0.0173 0.0019 0.0034 0.0160
GRMDMF)
Area under the 0.571 0.853 0.881 0.862 0.753 0.847 0.704 0.793 0.779 0.68
ROC curve (P=0.595) (P=0.0001) (P=0.0001) (P=0.0001) (P=0.0002) (P=0.0001) (P=0.0055) (P=0.0001) (P=0.0003) (P=0.022)
s.d., standard deviation; GRMDSF, GRMD dogs affected with the severe form; GRMDMF, GRMD dogs affected with the moderate form; ROC, receiver operating

































Fig. 2. Analysis of the expression of CD49d on
circulating T cells, and results in 2-month-old dogs
as a function of their clinical form. (A,B) Typical
CD49d cytometric profiles from a moderate form (A,
green frame) and a severe form (B, red frame). Upper
profiles show the profile of CD49d expression in CD4+
cells, and lower profiles in CD8+ cells. The population
expressing high levels of CD49d is located to the right of
the black dotted line drawn on the graphs. (C,D) Graphs
represent the comparison of the percentages of
CD4+CD49dhi and CD8+CD49dhi cells obtained in 2-
month-old GRMD dogs with would-be moderate forms
(GRMDMF; in green) versus severe forms (GRMDSF; in
red). The height of the histograms provides the mean,
and the error bars indicate ± 1 s.d. Individual values
have been superimposed on the histograms and are
represented by empty circles. **Significant difference

















In this study, we have demonstrated that a set of carefully selected
biomarkers can be used to predict the clinical evolution of GRMD
dogs, the reference preclinical model of DMD.
Owing to the strong histological and clinical similarities shared
with individuals with DMD, GRMD dogs have been shown to play
a key role in the translational approach to develop candidate
therapies for this disease. These canine counterparts of DMD
individuals represent the ideal model to assess the efficacy of
therapies at biochemical, histological and functional levels, in a
pathological context very close to the human situation (Banks and
Chamberlain, 2008; Bartlett et al., 1996).
The present study demonstrates that, by using these non-invasive
biomarkers obtained at early stages of the disease, GRMD dogs can
be separated into groups with slow or fast disease progression before
their inclusion into a therapeutic preclinical trial, thus reinforcing
the translational value of this animal model.
Predictive biomarkers will improve the translational power
of preclinical studies carried out on GRMD dogs
The novel predictive biomarkers we have identified offer the
opportunity for a better handling of inter-individual heterogeneity, a
prominent feature of GRMD dogs. Indeed, GRMD dogs are such a
faithful model of DMD that they also reproduce the clinical
heterogeneity seen in the human disease. However, in the context of
an animal model, this can be seen as a major drawback when
evaluating the effect of treatments, especially when the results are
obtained in order to be directly translated to humans (Banks and
Chamberlain, 2008). Recently, efforts have been undertaken to
develop novel evaluation tools that allow a reliable functional
evaluation of dogs, and are able to detect the effect of a treatment,
despite this clinical heterogeneity (Barthélémy et al., 2012; Marsh et
al., 2010; Thibaud et al., 2012). As a supplementary tool, the
knowledge of the clinical status of the dogs at the beginning of the
studies (i.e. possibility to divide dogs into groups with severe and
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Fig. 3. Analysis of the motor function and
results of the gait analysis, motor score and
creatine kinase level in 2-month-old dogs as a
function of their clinical form. (A,B) A 10-
second sample of dorso-ventral acceleration
curves at a trot from 2-month-old GRMD dogs
that went on to develop either the moderate (A;
green) or severe (B; red) form of the disease. It
should be noted that the frequency and amplitude
of the curves are lower in the case of the GRMD
dogs that went on to develop the severe form of
the disease. (C-J) Graphs represent the
comparison of the values obtained in 2-month-old
GRMD dogs that went on to develop the
moderate form (GRMDMF; in green) versus the
severe form (GRMDSF; in red). The height of the
histograms provides the mean and the error bars
indicate ± 1 s.d. Individual values have been
superimposed on the histograms and are
represented by empty circles. Significant
differences are represented by *P<0.05, **P<0.01
and ***P<0.001. (C) speed normalized by the
height at withers (HW); (D) stride frequency; (E)
stride length normalized by the height at withers
(HW); (F) total power; (G) force index; (H) gait


















moderate phenotype) would greatly increase the significance of the
results and their translational value. One can even imagine selecting
dogs upon their predicted evolution as an inclusion criterion. For
example, only dogs with a predicted loss of ambulation before 6
months of age would be included, to evaluate the effect of a given
treatment to prevent the loss of ambulation. In this case, the
maintenance of the ability to walk would be a positive result per se.
Moreover, such a selection of the dogs by their predicted clinical
profile would lead to homogeneous GRMD dog cohorts in preclinical
trials, and thus reduce the number of dogs required to demonstrate a
therapeutic effect, in the same way as it is envisioned in clinical trials
by stratifying patients upon their genotype regarding modifier genes
(Bello et al., 2012). This reduction in the number of dogs should lead
to faster preclinical results and consequently a faster initiation of
clinical trials. In conclusion, these predictive biomarkers could help
to accelerate the translational process of therapies for DMD.
Moreover, it should be noted that the biomarkers we have
presented in this study are ready to be used in predictive tests with
known thresholds, sensitivities and specificities. They are reliable,
easy and fast to obtain, and non-invasive (blood sample and gait
test). Their use before the initiation of a potential treatment is thus
a realistic proposal.
These predictive biomarkers common to DMD individuals
strengthen the translational value of the GRMD model
Another remarkable highlight of this study is the reinforcement of the
already known similarities that exist between DMD individuals and
the GRMD model. First, in a previous study we demonstrated that the
proportion of circulating lymphocytes expressing high levels of
CD49d is correlated with the severity of the phenotype in DMD
individuals, and is able to reliably predict the age at which ambulation
is lost (F.P.-M., W.S., S.D.S.-B., V.M., T.V., G.B.-B. et al., unpublished
data). In this study, we report the same finding in GRMD dogs, at
least for the CD4+ population. Secondly, the early gait abnormality
that we have described is also very close to what has been described
in DMD individuals. Indeed, it has been shown that the time to walk
30 feet, i.e. the spontaneous speed of gait, was strongly predictive of
the time at which ambulation was lost (McDonald et al., 1995).
Therefore, in both DMD individuals and GRMD dogs, the speed of
walking can be used to predict the loss of ambulation.
The fact that both DMD individuals and GRMD dogs share the
same predictive biomarkers is a new clue of the similarities existing
between these two diseases and it emphasizes the interest of the
GRMD model in translational research. Thus, GRMD dogs are not
only similar to DMD individuals from many points of view,
including clinical heterogeneity, but also their management during
therapeutic trials can be very close to what is done for DMD
individuals: similar evaluation tools have been developed for both
species and this is now supported by reliable predictive biomarkers.
Therapies targeting DMD can thus be preclinically tested in the
same pathological and clinical context, using the same evaluation
tools and the same biomarkers as controls of the ‘should-be’ clinical
situation, optimizing the translation of results from the preclinical
model to individuals with DMD.
Limitations
Despite the step forward in preclinical trials for DMD provided by
the identification of these new predictive biomarkers in GRMD
dogs, this study also presents some limitations. First, because of the
small number of dogs that were co-tested it was not possible to test
the interaction that exists between lymphocytes and gait biomarkers.
This should of course be done in future experiments, in order to
propose a combined predictive test with an improved robustness,
and also to better understand how these two features might interact.
Indeed, even if gait modifications are complicated to decipher, and
to link to a particular pathogenic pathway, because they result from
a very global functional evaluation, they could originate from an
enhanced muscle inflammation in severely affected animals, as
suggested by the circulating lymphocyte biomarker. A more active
inflammatory process in severely affected dogs, at least partly due
to CD49dhi-expressing T-cell migration to muscles, could negatively
impact ambulation either directly by inducing muscle pain, or by
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Table 2. Results of the spline function analysis of the association
between age at loss of ambulation and speed/HW at 2 months of
age
Speed/HW (s−1) aHRs Lower limit 95% CI Upper limit 95% CI
2 65.71** 6.12 705.88
2.5 17.7** 3.57 87.8
3 5.28** 2.14 13.05
3.5 1.95** 1.37 2.78
4 1 – – 
4.5 0.76* 0.6 0.96
5 0.8 0.47 1.38
5.5 1.08 0.4 2.93
6 1.68 0.35 8.09
aHR, hazard ratio adjusted for BMI, leucocytes number and carpal
contracture; CI, confidence interval; *P<0.05; **P<0.01.
Fig. 4. Association between the age at which ambulation
was lost and speed/HW at 2 months of age using a spline
function with three knots. Adjusted spline function analysis
of the association between age at loss of ambulation and
speed normalized by height at withers (HW), with three knots
located at the 5th, 50th and 95th percentiles. This curve
illustrates the very high hazard ratios at low speed/HW
values. For example, dogs with a value of speed/HW of 2.5
second−1 have an increased risk for loss of ambulation of
17.70 (95% CI, 3.57-87.80; P<0.01) compared with dogs with
a value of speed/HW of 4 seconds−1 (median of the whole
population). The individual values of speed/HW are
schematized under the graph (crosses). HW, height at
















leading to increased muscle fibrosis, as described in affected
individuals with more severe clinical presentations (Desguerre et al.,
2009b). This aspect still remains to be investigated in GRMD dogs,
using either muscle imaging and/or biopsies.
Furthermore, the objective of this work, which has been achieved,
was to provide tools to improve the handling of GRMD dogs, but
these biomarkers now have to be better understood from a
mechanistic point of view. Further experiments will have to be
carried out to explain the early modification of these biomarkers in
dogs with severe forms of the disease. In individuals with DMD, it
has been shown that a larger number of CD4+ and CD8+ CD49dhi
circulating cells are present in severely affected individuals; in
comparison to the same subset of cells in healthy individuals, these
cells in DMD individuals have an enhanced migration capacity, and
are also a component of the lymphocytic population present in the
muscles, where they probably contribute to the deleterious
inflammatory process (F.P.-M., W.S., S.D.S.-B., V.M., T.V., G.B.-B.
et al., unpublished data). Preliminary data obtained on GRMD
muscle biopsies show that CD4+CD49d+ cells can be found in the
inflammatory infiltrate like in DMD patients, but a correlation to the
level of circulating TCD4+CD49dhi cells remains to be assessed. A
characterization of the inflammatory process in GRMD muscles will
have to be performed in the future and compared to what is known
in DMD, to explain some differences with the human context;
notably, why the expression of CD49d on CD8+ cells is not modified
in the canine species.
These predictive biomarkers could help to validate
modulatory pathways of both the canine and human
diseases
In response to these limitations, further experiments should focus on
the mechanisms that underlie the modifications of these biomarkers
in severely affected dogs and humans. In this context, the GRMD
dog is a favorable model to study inter-individual heterogeneity,
because all the dogs share the same mutation in the dystrophin gene,
the same environmental conditions and the same clinical
management. It is thus much easier to work on modulatory
pathways of the disease in dogs than in humans. Further
experiments, including in vitro migration assays and in vivo
pharmacological blocking of CD49d, will maybe confirm the
CD49d-driven inflammation hypothesis. This canine cohort should
also be genotyped for genetic modifiers of the human disease
severity (Flanigan et al., 2013; Pegoraro et al., 2011), the LTBP4 and
SPP1 genes, in order to determine to what extent the canine
situation is comparable to the human one. This genetic investigation
would also represent the opportunity to study the potential link
between the CD49dhi T cells, SPP1 and LTBP4 biomarkers in the
same individuals. This could help to confirm the presumed role of
the TGFβ pathway in the modulation of disease severity (Bartolomé
et al., 2003; Flanigan et al., 2013), or to link these biomarkers to
other pathogenic pathways, paving the way for new therapeutic
targets translatable from GRMD to DMD.
Conclusion
This study, carried out on the canine preclinical model of DMD, has
taken advantage of its well-known inter-individual heterogeneity,
one of the numerous common features with DMD, to identify
predictive biomarkers of disease evolution. Lymphocytic and gait
biomarkers, common to DMD patients, were successfully found to
be able to predict severe forms of the canine disease. This study
enhances the already high translational value for DMD of results
obtained on GRMD dogs, by reinforcing the similarities between
dogs and humans affected with muscular dystrophies, and by
providing new tools to overcome the issue of inter-individual
heterogeneity and to improve the quality of preclinical trials
involving GRMD dogs. Finally, these biomarkers represent new
avenues to explore in order to better understand clinical
heterogeneity, and an opportunity to identify major modulatory
pathways in dystrophin-deficient disease.
MATERIALS AND METHODS
GRMD dogs
All procedures were approved by the common ethical committee of the
ANSES, ENVA and UPEC (ComEth ANSES/ENVA/UPEC), under the
approval number 11/01/11-07.
The GRMD dogs included in this study were housed in the facilities of
the neurobiology laboratory of the Veterinary School of Alfort. They were
genotyped before the age of 2 months, as previously described (Bartlett et
al., 1996). Healthy littermates matched for both gender and age were used
as controls for the cytofluorometric experiments. The GRMD dogs were part
of a natural history study, and a regular clinical follow-up was carried out
throughout their whole life. Over a period of 4 years, a total of 61 GRMD
dogs were included in the study; they were all tested at 2 months of age, and
categorized at 6 months of age upon their ambulation status: ambulant at 6
months of age (moderate form) versus non-ambulant at 6 months of age
(severe form). Data regarding the age at which ambulation was lost, if this
event occurred, were also collected.
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Fig. 5. ROC curves of the candidate markers for a
predictive test. The ROC curves of the ten parameters tested
for their ability to predict severe forms are schematized on this
graph. Each marker is represented by a specific color,
indicated in the key on the right. Note that the curves with the
highest areas under the curve (AUC) are those obtained using
the speed (AUC=0.881) and the stride frequency
(AUC=0.862). Another interesting point is that the percentage
of CD4+CD49dhi (AUC=0.853) remains highly specific (100%)
until relatively high levels of sensitivity (44%). HW, height at


















Of the 61 GRMD dogs included in the study, 35 underwent an 8 ml venous
blood sample at 2 months of age and were compared with eight healthy
littermates. Among these 35 GRMD dogs, 26 were categorized as moderate
forms, and nine as severe forms at 6 months of age. At the time of sampling,
the dogs were checked for concurrent infections and, particularly, aspiration
pneumonias. A blood cell count was also performed, as well as a
biochemical assessment including a serum creatine kinase (CK) activity
measurement.
Cytometry
For cytometry, we used fluorochrome-labeled monoclonal antibodies with
specificities for CD3, CD4, CD8 (Serotec, Kidlington, UK) and CD49d
(Pharmingen/Becton Dickinson, San Diego, CA, USA). Isotype/
fluorochrome-matched unrelated antibodies were obtained from
Pharmingen/Becton Dickinson. Peripheral blood mononuclear cells
(PBMCs) from GRMD and healthy controls were isolated through ficoll-
histopaque (Sigma-Aldrich, St Louis, MO, USA) sedimentation, using
freshly obtained samples. PBMCs were first incubated in 96-well plates –
with 5% fetal calf serum for 20 minutes at 4°C – and then subjected to
fluorochrome-labeled primary monoclonal antibodies for 30 minutes. After
washing, cells were fixed and acquisition for flow cytometry was carried out
using a LSR II® flow cytometer (Becton Dickinson, San Jose, CA, USA)
equipped with FacsDiva software. A cell gate excluding cell debris and non-
viable cells was determined using forward versus side scatter parameters.
Analyses were done after recording 20,000 events for each sample, using
the FACS Diva software.
Functional motor assessment
Among the 61 GRMD dogs included in the study, 57 2 month-old GRMD
dogs underwent a locomotor evaluation encompassing a clinical motor
score, as well as a 3D-accelerometry test. Among them, 15 were then
classified as severe forms owing to a loss of ambulation before 6 months of
age.
The clinical motor score was performed using a previously described
scoring grid (Barthélémy et al., 2012; Thibaud et al., 2007), containing 11
items; the higher the score, the more severe was the motor phenotype. The
motor score was expressed as a percentage of the maximal score.
The 3D-accelerometry test was performed as previously described using
a dedicated device (Locometrix®, Centaure Metrix, Evry, France) intending
to record three-axial accelerations near the center of gravity during
spontaneous gait (Barthélémy et al., 2009). Ten previously described
variables were calculated from the acceleration curves in the software
Equimetrix® and are as follows: the speed (m/s), the stride frequency
(cycles/s), the stride length (m), the regularity, the dorso-ventral, cranio-
caudal and medio-lateral powers (W/kg), the total power (W/kg), the force
index [expressed in N/kg body weight, and calculated by normalizing the
total power (W/kg) by the speed (m/s)], and a gait quality index
recapitulating the association of seven variables. The speed and stride length,
because directly influenced by the dog size, were normalized by the height
at the withers (HW, m), and the axial powers were expressed as a proportion
of the total power (%).
Statistical analyses
Univariate comparisons between severe and moderate forms were assessed
using chi-square or Student’s t-tests for categorical (e.g. the gait type) or
continuously distributed variables, respectively.
For each biomarker that was associated with loss of ambulation at 6
months (i.e. severe versus moderate form) with a P-value <0.05, a receiver
operating characteristics (ROC) curve was used to evaluate the effectiveness
of the biomarker for distinguishing dogs with the severe form from those
with moderate form.
Survival analyses were performed to assess the association between time
to loss of ambulation and three following exposure variables: (1) proportion
of CD4+CD49dhigh T cells, (2) stride frequency, or (3) speed normalized by
the height. Univariate and multivariate Cox proportional hazard models were
used for each of the three exposure variables. The candidates for potential
confounding variables were: body mass (kg), body mass index [BMI;
calculated by dividing the body mass (kg) by the height at withers (m2)],
presence of a carpal contracture, and blood leucocytes number. These last
three candidates were associated with loss of ambulation with a P-value
<0.20 in univariate analyses and were therefore included into each
multivariate Cox model.
Spline functions (Desquilbet and Mariotti, 2010) were used to check the
linearity assumption for each of the three exposure variables; this
assumption was valid (i.e. P-value for a non-linear association >0.30) for
the proportion of CD4+CD49dhigh T cells and stride frequency, but not for
speed normalized by the height (P-value for a non-linear association <0.01).
In the latter model, a spline function with three knots located at the 5th, 50th
and 95th percentiles was used for speed normalized by the height. For
optimal adjustments, BMI as well as a leucocytes were both included using
spline functions with three knots located at the 5th, 50th, and 95th
percentiles (Desquilbet and Mariotti, 2010).
Analyses were conducted using Statistica (version 10, Stat Soft, Maisons-
Alfort, France) and SAS® V9.2 (SAS Institute, Cary NC) software. The level
of significance was set at 0.05.
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